NES and myeloproliferative neoplasm: Treatment with β3-AR agonists restore the sympathetic regulation of nestin(+) mesenchymal stem cells, blocking myeloproliferative neoplasms progression by indirectly reducing the number of leukaemic stem cells (Arranz et al., 2014).